Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

Article content material

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group”) (CSE:PSYG), a clinical-stage life science biotechnology firm pioneering the usage of nature-derived psilocybin in psychological well being and wellbeing, right now introduced that its subsidiary, Psyence Biomedical Ltd (“Pubco”), has entered right into a definitive securities buy settlement (the “Securities Buy Settlement”) offering for as much as US$10 million in funding by the issuance of as much as 4 senior secured convertible notes (the “Notes” and “Be aware Financing”, respectively) with a US primarily based funding agency (the “Purchaser”).

Article content material

The Be aware Financing is predicted to offer Pubco roughly USD$2.5 million in funding at closing, which is predicted to shut instantly previous to or concurrently with the closing of the beforehand introduced enterprise mixture with Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a particular objective acquisition firm, and Pubco (the “Enterprise Mixture”). 

Article content material

“This funding is an extremely thrilling milestone for Psyence, as we make enormous strides in our progress in the direction of itemizing our scientific trial enterprise on Nasdaq,” mentioned Dr Neil Maresky, the CEO of Psyence Group. “It alerts a perception within the work we’re doing at Psyence, permitting us to execute our technique and additional our analysis in palliative care.”

Be aware Financing

Pursuant to the Securities Buy Settlement, the Be aware Financing supplies for the issuance of the Notes within the mixture principal quantity of as much as USD$12.5 million to the Purchaser.

The Be aware Financing can be supplied in 4 equal tranches (every a “Tranche”) of USD$3,125,000 of principal in trade for a complete of USD$2,500,000 in mixture proceeds (i.e. the mortgage quantity) per Tranche. The primary Tranche is predicted to shut instantly previous to or concurrent with the closing of the beforehand introduced Enterprise Mixture. The second Tranche funding is conditioned upon the SEC having declared efficient a resale registration assertion registering for resale the shares of Pubco’s frequent inventory underlying the Be aware issued to the Purchaser, in reference to the primary Tranche, together with sure different circumstances, and could also be funded, in full or in instalments, over a time period primarily based on the median of the day by day worth of the PubCo frequent shares (“Frequent Shares”) over an outlined interval. Funding of the third and fourth Tranches are on the full discretion of the Purchaser.

Article content material

Article content material

The Purchaser will obtain a structuring payment equal to an mixture of three,000,000 Frequent Shares of PubCo, of which 1,300,000 Frequent Shares can be delivered to the Purchaser on the closing of the Enterprise Mixture, with the remaining 1,700,000 shares being issuable to the Purchaser upon the train of a name choice granted to the Purchaser.

The Notes will bear curiosity at 8% every year, paid month-to-month in arrears, and can carry a time period of 36 months. Curiosity could also be settled in money or in Frequent Shares on the election of PubCo on the conversion value decided underneath the phrases of the Notes.

At any time following one 12 months after the unique problem date of the Be aware, and supplied that no occasion of default is constant on the relevant prepayment date, PubCo could repay any portion of the excellent principal quantity of the Be aware upon at the very least 30 buying and selling days’ written discover by paying an quantity equal to 130% of the principal quantity of the Be aware then being pay as you go, plus accrued however unpaid curiosity by the prepayment date.

Completion of the Be aware Financing is topic to, amongst different issues, the satisfaction of the circumstances negotiated within the Securities Buy Settlement. Accordingly, there may be no assurance that the Be aware Financing can be consummated on the phrases or timeframe presently contemplated, or in any respect.

Article content material

Further Data and The place to Discover It

In reference to the beforehand introduced Enterprise Mixture, Pubco has filed with the SEC a Registration Assertion on Kind F-4 (Registration No. 333-273553) (the “Registration Assertion”), which incorporates the proxy assertion for a gathering of Newcourt shareholders and a prospectus for the issuance of Pubco securities in reference to the Enterprise Mixture (the “Proxy Assertion/Prospectus”). The Registration Assertion was declared efficient on November 13, 2023. Newcourt has mailed the Proxy Assertion/Prospectus and different related paperwork to its shareholders. This doc isn’t an alternative choice to the Proxy Assertion/Prospectus/Consent Solicitation Assertion. INVESTORS AND SECURITY HOLDERS AND OTHER INTERESTED PARTIES ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT HAVE BEEN FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PSYENCE GROUP, PUBCO AND NEWCOURT, THE PROPOSED TRANSACTION AND RELATED MATTERS. The paperwork filed or that can be filed with the SEC referring to the Enterprise Mixture (when they’re out there) may be obtained freed from cost from the SEC’s web site at www.sec.gov.

Article content material

No Supply or Solicitation

This communication is for informational functions solely and isn’t meant to and doesn’t represent, or type part of, a suggestion, invitation or the solicitation of a suggestion or invitation to buy, in any other case purchase, subscribe for, promote or in any other case eliminate any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed enterprise mixture or in any other case, nor shall there be any sale, issuance or switch of securities in any jurisdiction in contravention of relevant legislation. 

Individuals within the Solicitation

Newcourt, Psyence, the opposite events to that sure Amended and Restated Enterprise Mixture Settlement, dated as of July 31, 2023 (the “Enterprise Mixture Settlement”), and their respective administrators and govt officers, different members of administration and workers could also be thought-about members within the solicitation of proxies with respect to the potential transaction described on this communication underneath the principles of the SEC. Details about the administrators and govt officers of Newcourt is about forth in Newcourt’s filings with the SEC. Data relating to different individuals who could, underneath the principles of the SEC, be deemed members within the solicitation of the shareholders in reference to the Enterprise Mixture and an outline of their pursuits are set forth within the Registration Assertion. These paperwork may be obtained freed from cost from the sources indicated above.

Article content material

WeirFoulds LLP is appearing as Canadian authorized advisor and Ellenoff Grossman & Schole LLP is appearing as U.S. authorized advisor to Psyence. McDermott Will & Emery is appearing as U.S. authorized advisor to Newcourt.

Ahead Trying Statements

This communication accommodates “forward-looking statements” inside the which means of the Non-public Securities Litigation Reform Act of 1995. Such statements embody, however should not restricted to, statements about future monetary and working outcomes, our plans, targets, expectations and intentions with respect to future operations, services and products; and different statements recognized by phrases comparable to “will doubtless consequence,” “are anticipated to,” “will proceed,” “is anticipated,” “estimated,” “consider,” “intend,” “plan,” “projection,” “outlook” or phrases of comparable which means.

Ahead-looking statements on this communication embody statements relating to the meant closing of the Enterprise Mixture, the buying and selling of Pubco securities on the Nasdaq, and the completion of the Be aware Financing. These forward-looking statements are primarily based on quite a lot of assumptions, together with the assumptions that the closing circumstances to the Enterprise Mixture can be met and that Newcourt will acquire the required regulatory and shareholder approvals to finish the Enterprise Mixture. There are quite a few dangers and uncertainties which will trigger precise outcomes or efficiency to be materially completely different from these expressed or implied by these forward-looking statements. These dangers and uncertainties embody, amongst others: the lack to finish the Enterprise Mixture and failure to acquire the requisite shareholder and regulatory approvals required for the buying and selling of Pubco securities on the Nasdaq. The foregoing record of things isn’t exhaustive. You need to rigorously contemplate the foregoing components and the opposite dangers and uncertainties described within the “Danger Components” part of the Registration Assertion referenced above and different paperwork filed by Newcourt and Pubco once in a while with the SEC. These filings establish and handle different necessary dangers and uncertainties that might trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Precise outcomes and future occasions may differ materially from these anticipated in such data. Nothing on this communication needs to be considered a illustration by any individual that the forward-looking statements set forth herein can be achieved or that any of the contemplated outcomes of such forward-looking statements can be achieved. You shouldn’t place undue reliance on forward-looking statements, which converse solely as of the date they’re made. Besides as required by legislation, Newcourt and Psyence don’t intend to replace these forward-looking statements.

Article content material

For additional data, please contact:
Electronic mail: ir@psyence.com
Media Inquiries: media@psyence.com
Normal Data: information@psyence.com

Telephone: +1 416-477-1708

About Psyence Group and Psyence Biomed:

Psyence is a life science biotechnology firm listed on the Canadian Securities Trade (CSE: PSYG), with a give attention to pure psychedelics. The Psyence Biomed Division works with pure psilocybin merchandise for the therapeutic of psychological trauma and its psychological well being penalties within the context of palliative care. Our title “Psyence” combines the phrases psychedelic and science to affirm our dedication to producing psychedelic medicines developed by evidence-based analysis.

Knowledgeable by nature and guided by science, we constructed and function one of many world’s first federally licensed industrial psilocybin mushroom cultivation and manufacturing services in Southern Africa. Our group brings worldwide expertise in each enterprise and science and contains consultants in mycology, neurology, palliative care, and drug improvement. We work to develop superior pure psilocybin merchandise for scientific analysis and improvement. Our key divisions, Psyence Manufacturing, Psyence Therapeutics and Psyence Operate, anchor a global collaboration, with operations in Canada, the UK, Southern Africa, Australia, and a presence in the US.

Be taught extra at www.psyence.com and on Twitter, Instagram and LinkedIn.

About Newcourt Acquisition Firm:

Newcourt Acquisition Firm is a Particular Objective Acquisition Firm (SPAC) dedicated to figuring out and merging with high-potential firms. Newcourt focuses on creating worth for its shareholders by facilitating strategic enterprise combos with firms that display robust progress prospects and a dedication to excellence.

Article content material